Deal Snapshot
TOCAGEN, FORTE BIOSCIENCES MERGE
Tuesday 25 February 2020

California-based gene therapy company Tocagen Inc. (NASDAQ: TOCA) has entered into a merger agreement with California-based biopharmaceutical company and Forte Biosciences, Inc., in an all-stock transaction focussed on advancing Forte's clinical programme in atopic dermatitis, the company said.
Upon stockholder approval, the combined company is expected to operate under the name Forte Biosciences and trade on the NASDAQ Capital Market under the ticker symbol FBRX.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 25/02/2020
Target: Tocagen Inc
Country: USA
Deal Size: 25m (USD)
Sector: Pharmaceuticals
Type: Merger
Financing: Stock
Status: Agreed
Vendor:
Buyer: Forte Biosciences, Inc
Buyer Advisor: Wilson Sonsini Goodrich and Rosati
Comment:
Tocagen equity holders, immediately prior to the merger, will own approximately 25.5% of the combined company and Forte equityholders immediately prior to the merger will own approximately 74.5% of the combined company

Options